Proteolytic Inhibition in Regulating the Insulin-Like Growth Factor-Binding Proteins in Prostate Cancer
暂无分享,去创建一个
Barry S. Cooperman | B. Cooperman | Catherine Yang | Catherine F. Yang | Weixing Li | Weixing Li | Rob Zakreski | Xiaoyang Mou | Nikita Iltchenko | Xiaoyang Mou | Rob Zakreski | N. Iltchenko
[1] S. Nemoto,et al. Ageing and the mystery at Arles , 2004, Nature.
[2] L. Giudice,et al. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. , 1993, Growth regulation.
[3] T. Rohan,et al. Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.
[4] R. Stock,et al. Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.
[5] D. Peehl,et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.
[6] U Winkler,et al. Synthesis and evaluation of diphenyl phosphonate esters as inhibitors of the trypsin-like granzymes A and K and mast cell tryptase. , 1998, Journal of medicinal chemistry.
[7] J. Fowlkes,et al. Characterization of Glycosaminoglycan-binding Domains Present in Insulin-like Growth Factor-binding Protein-3* , 1996, The Journal of Biological Chemistry.
[8] R. Norton,et al. IGF-binding proteins – the pieces are falling into place , 2005, Trends in Endocrinology & Metabolism.
[9] M. Webber,et al. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] S. Chernausek,et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. , 1994, Endocrinology.
[11] S. Afford,et al. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. , 1994, The Journal of clinical endocrinology and metabolism.
[12] M. Rechler,et al. Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[13] B. Katzenellenbogen,et al. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. , 1990, Endocrinology.
[14] J. Powers,et al. Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. , 1991, Biochemistry.
[15] A. Grimberg. P53 and IGFBP-3: apoptosis and cancer protection. , 2000, Molecular genetics and metabolism.
[16] B. Cooperman,et al. The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). , 2000, Biochimica et biophysica acta.
[17] J. Weiler,et al. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. , 1995, Growth regulation.
[18] D. Leroith,et al. The new kid on the block(ade) of the IGF-1 receptor. , 2004, Cancer cell.
[19] H. Lilja,et al. Enzymatic action of prostate‐specific antigen (PSA or hK3): Substrate specificity and regulation by Zn2+, a tight‐binding inhibitor , 2000, The Prostate.
[20] J. Holaday,et al. Antiangiogenic activity of prostate-specific antigen. , 1999, Journal of the National Cancer Institute.
[21] D. Tindall,et al. In situ hybridization of prostate-specific antigen mRNA in human prostate. , 1990, The Journal of urology.
[22] M. Hendrix,et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.
[23] B. Cooperman,et al. Design of synthetic hexapeptide substrates for prostate-specific antigen using single-position minilibraries. , 1999, The journal of peptide research : official journal of the American Peptide Society.
[24] S. Hankinson,et al. Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.
[25] R B Brandt,et al. Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. , 1987, Biochemical medicine and metabolic biology.
[26] H. Lilja. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.
[27] I. Campbell,et al. Structure of the fibronectin type 1 module , 1990, Nature.
[28] H. Lilja,et al. Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.
[29] D. Farquhar,et al. Biologically reversible phosphate-protective groups. , 1983, Journal of pharmaceutical sciences.
[30] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[31] L. Giudice,et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.
[32] J. Clements,et al. The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers , 2004, Critical reviews in clinical laboratory sciences.
[33] E. De Clercq,et al. cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. , 1998, Journal of medicinal chemistry.
[34] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[35] G. Murphy,et al. Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.
[36] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[37] E. Webb,et al. Non-Inverted Versus Inverted Plots in Enzyme Kinetics , 1959, Nature.
[38] J. Powers,et al. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. , 1994, Journal of medicinal chemistry.
[39] P. Cohen,et al. Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.
[40] R. Baxter,et al. Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.
[41] M. Schachter. Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions. , 1979, Pharmacological reviews.
[42] S. Mohan,et al. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.
[43] R. Maronpot,et al. Inhibition of the enzymatic activity of prostate‐specific antigen by boric acid and 3‐nitrophenyl boronic acid , 2003, The Prostate.
[44] T. Stamey,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.
[45] L. Murphy,et al. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. , 2001, The Journal of clinical endocrinology and metabolism.
[46] S A Newman,et al. Different roles for fibronectin in the generation of fore and hind limb precartilage condensations. , 1995, Developmental biology.
[47] A. Hoeflich,et al. Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. , 2005, Endocrinology.
[48] J. Silha,et al. Insulin-like growth factor binding proteins in development. , 2005, Advances in experimental medicine and biology.
[49] M. Papa,et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.
[50] D. Farquhar,et al. Bioreversible phosphate protective groups: Synthesis and stability of model acyloxymethyl phosphates , 1984 .